ABIVAX Société Anonyme (ABVX) Rumored To Attract Interest From Eli Lilly

ABIVAX Société Anonyme (NASDAQ:ABVX) is among the 20 Best Performing Stocks in 2025.

ABIVAX Société Anonyme (ABVX) Rumored To Attract Interest From Eli Lilly, La Tribune Says

According to a story in the French-language newspaper La Tribune on December 24, 2025, there have been rumors that Eli Lilly has been drawing interest in the French biotechnology business ABIVAX Société Anonyme (NASDAQ:ABVX), TheFly reported. Its shares surged after the release, rising $4.62, or 3%, to $142.97 in pre-market trade in New York.

The company also declared that it was going to be included in the Nasdaq Biotechnology Index. The inclusion went into effect on Monday, December 22, 2025.

Thefly revealed on December 18, 2025, that Guggenheim analyst Yatin Suneja has increased the company’s price objective for ABIVAX Société Anonyme (NASDAQ:ABVX) from $150 to $175. The analyst maintained a Buy rating for the stock. Guggenheim’s positive forecast for obefazimod ahead of an impending 44-week maintenance readout is the basis for the price target hike.

The firm has €589.7 million in cash despite high R&D-driven losses and a €15.3 million monthly cash burn.

Nonetheless, the stock is down by 10.04% YTD as of January 6, 2026.

While we acknowledge the risk and potential of ABVX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ABVX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025.

Disclosure. None